drugset / Trial / NCT01215084

A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers

NCT01215084

Phase 1 Completed 36 enrolled Biogen Acorda Therapeutics · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective of the study is to determine the Pharmacokinetic (PK) and safety profiles of fampridine-PR 10 mg in Chinese and Japanese adult healthy volunteers. The secondary objective of this study is to compare the PK and safety profiles of fampridine-PR 10 mg among the Chinese, Japanese, and Caucasian adult healthy volunteers.

Timeline

Start
2010-10
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalfampridine Small molecule 10 mg Oral

Indications

No indication recorded.